Findings of Research Misconduct, 48034-48036 [2022-16867]
Download as PDF
<![CDATA[
48034
Federal Register / Vol. 87, No. 150 / Friday, August 5, 2022 / Notices
adults in their transition from foster care
to independent living in the areas of
education, employment and earnings,
housing and economic well-being,
social support, well-being, health and
safety, and criminal involvement. It
focuses on helping young adults
identify and achieve their goals while
developing the skills necessary for
independent living.
The evaluation is part of a larger
project to help ACF build the evidence
base in child welfare through rigorous
evaluation of programs, practices, and
policies. The activities and products
from this project will contribute to
evidence building in child welfare and
help to determine the effectiveness of a
program for youth formerly in foster
care on young adult outcomes.
The implementation study will collect
information through video conferences
and site visits to the participating
program and child welfare agency. Data
collection activities for the
implementation study began, as
previously approved by OMB.
Additional protocols are proposed as
part of the implementation study.
Proposed information collection
activities include interviews and focus
groups with administrators and staff
from the program developer, child
welfare agency, and program providers;
online survey of program staff;
interviews with youth who participated
in the program; and focus groups with
youth who participated in the program
and who received services as usual.
Respondents: Program participants,
young adults receiving services as usual,
agency and program administrators and
staff, other program stakeholders.
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
(total over
request
period)
Respondents
Number of
responses per
respondent
(total over
request
period)
Average
burden per
response
(in hours)
Total burden
(in hours)
Annual burden
(in hours)
Burden for previously approved, ongoing data collection
Site Visit 2 Focus Group
Guide for Staff.
LifeSet Specialists ..............
12
1
1.5
18
9
470
1
0.6
282
141
12
1
5
60
30
LifeSet Team Supervisors
Baseline Youth Survey .......
Administrative data file ........
Youth Formerly in Foster
Care.
Agency and Program Staff
Burden for newly requested information collection
Site Visit 3 Interview Guide
for Administrators.
Site Visit 3 Focus Group
Guide for Staff.
lotter on DSK11XQN23PROD with NOTICES1
LifeSet Specialist Survey ....
Interview Guide for Youth ...
Focus Group Guide for
Youth.
Child Welfare Agency Administrators.
Licensed LifeSet Experts
Provider Agency Administrators
LifeSet Developer Administrators
Provider Agency Administrators
LifeSet Specialists ..............
LifeSet Team Supervisors
Child Welfare Agency
Caseworkers
LifeSet Specialists ..............
LifeSet Program Youth .......
LifeSet Program Youth .......
Services As Usual Youth
Estimated Total Annual Burden
Hours: 269.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
VerDate Sep<11>2014
17:20 Aug 04, 2022
Jkt 256001
22
1
1
22
11
28
1
1.5
42
21
16
12
64
1
1
1
.3
1
1.5
5
12
96
3
6
48
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C. 677.
Frm 00078
Fmt 4703
Sfmt 4703
Findings of Research Misconduct
ACTION:
[FR Doc. 2022–16791 Filed 8–4–22; 8:45 am]
PO 00000
Office of the Secretary
AGENCY:
Mary B. Jones,
ACF/OPRE Certifying Officer.
BILLING CODE 4184–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary, HHS.
Notice.
Findings of research
misconduct have been made against
Janina Jiang, M.D., Ph.D. (Respondent),
former Assistant Researcher in the
Department of Pathology & Laboratory
Medicine at the David Geffen School of
SUMMARY:
E:\FR\FM\05AUN1.SGM
05AUN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 150 / Friday, August 5, 2022 / Notices
Medicine, University of California, Los
Angeles (UCLA). Respondent engaged in
research misconduct in research
included in grant applications
submitted for U.S. Public Health Service
(PHS) funds, specifically R43
CA228629–01 submitted to the National
Cancer Institute (NCI), National
Institutes of Health (NIH), UL1
TR000124 submitted to the National
Center for Advancing Translational
Sciences (NCATS), NIH, and P01
AI131294–01, R01 AI126914–01, R21
AI131013–01, R21 AI131451–01, R21
AI131451–01A1, R21 AI142068–01, R43
AI136224–01, R44 AI126960–01, and
R44 AI128983–01 submitted to the
National Institute of Allergy and
Infectious Diseases (NIAID), NIH. The
administrative actions, including
supervision for a period of three (3)
years, were implemented beginning on
July 22, 2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Janina Jiang, M.D., Ph.D., University
of California, Los Angeles: Based on the
report of an investigation conducted by
UCLA and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Janina Jiang,
former Assistant Researcher in the
Department of Pathology & Laboratory
Medicine at the David Geffen School of
Medicine, UCLA, engaged in research
misconduct in research included in
grant applications submitted for PHS
funds, specifically R43 CA228629–01
submitted to NCI, NIH, UL1 TR000124
submitted to NCATS, NIH, and P01
AI131294–01, R01 AI126914–01, R21
AI131013–01, R21 AI131451–01, R21
AI131451–01A1, R21 AI142068–01, R43
AI136224–01, R44 AI126960–01, and
R44 AI128983–01 submitted to NIAID,
NIH.
ORI found that Respondent engaged
in research misconduct by knowingly
and recklessly falsifying and/or
fabricating flow cytometry data that
were included in the following eleven
(11) grant applications submitted for
PHS funds:
• R43 CA228629–01, ‘‘CTL Based
Therapeutic Vaccine to Prevent or
Interrupt HPV Mediated Oncogenesis,’’
submitted to NCI, NIH, Awarded Project
Dates: September 18, 2018-February 29,
2020.
• UL1 TR000124, ‘‘UCLA Clinical
and Translational Science Institute,’’
VerDate Sep<11>2014
17:20 Aug 04, 2022
Jkt 256001
submitted to NCATS, NIH, Awarded
Project Dates: June 1, 2011-August 31,
2016.
• P01 AI131294–01, ‘‘Defining
Factors Controlling HIV Rebound,’’
submitted to NIAID, NIH, Awarded
Project Dates: August 10, 2017-July 31,
2022.
• R01 AI126914–01, ‘‘A Recombinant
Human Vault CTL-Based HIV Vaccine
Component,’’ submitted to NIAID, NIH,
on December 23, 2015.
• R21 AI131013–01, ‘‘A Novel
Cellular Immune Zika Vaccine,’’
submitted to NIAID, NIH, on June 14,
2016.
• R21 AI131451–01, ‘‘A Novel
Therapeutic Vaccine for HPV
Oncogenesis,’’ submitted to NIAID, NIH,
on June 14, 2016.
• R21 AI131451–01A1, ‘‘A Novel
Therapeutic Vaccine for HPV
Oncogenesis,’’ submitted to NIAID, NIH,
on June 13, 2017.
• R21 AI142068–01, ‘‘A Novel
Therapeutic Vaccine for HPV
Oncogenesis,’’ submitted to NIAID, NIH,
on February 12, 2018.
• R43 AI136224–01, ‘‘Development of
A Novel Pan-Serovar Vaccine for
Chlamydia,’’ submitted to NIAID, NIH,
on April 5, 2017.
• R44 AI126960–01, ‘‘Novel PanSerovar Vaccine for Chlamydia,’’
submitted to NIAID, NIH, on January 4,
2016.
• R44 AI128983–01, ‘‘Design of a
Novel CTL Retargeting Therapeutic HIV
Vaccine,’’ submitted to NIAID, NIH, on
April 2, 2016.
ORI found that Respondent
knowingly and recklessly falsified and/
or fabricated flow cytometry data to
represent interferon-g (IFN-g) expression
in immune cells of mice administered
with human recombinant vaults such
that the represented data were
incompatible with the raw experimental
data. Specifically, Respondent falsified
and/or fabricated flow cytometry data to
represent:
• IFN-g expression in the immune
cells of mice injected subcutaneously or
intranasally with human recombinant
vaults containing HIV Gag peptides
such that the vaccinated arm of the
experiment showed antigen-specific Tcell responses in:
—Figure 6 of UL1 TR000124
—Figure 2 of R43 CA228629–01
—Figure 8 of R21 AI131451–01
—Figure 9 of R21 AI131451–01A1
—Figure 9 of R44 AI126960–01
—Figure 3 of R43 AI136224–01
—Figure 9 of R21 AI131013–01
—Figure 7 of R01 AI126914–01
—Figure 7 of R44 AI128983–01
—Figures 8A and 8B of R21 AI142068–
01
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
48035
• increased IFN-g expression in the
immune cells of mice injected with
human recombinant vaults containing
HPV peptides in Figure 3 of R43
CA228629–01
• dose-dependent increase in IFN-g
expression in the immune cells of mice
injected with human recombinant vaults
containing HIV Gag peptides in Figure
8 of P01 AI131294–01 and Figure 8C of
R21 AI142068–01
• IFN-g expression in the immune
cells of mice administered intranasally
with human recombinant vaults
containing HPV peptides in Figure 10 of
R21 AI131451–01A1 and Figure 10 of
R21 AI142068–01
• IFN-g expression in the immune
cells of mice administered orally with
human recombinant vaults containing
HIV Gag peptides in Figure 11 of R21
AI131451–01A1 and Figure 9 of R21
AI142068–01
• IFN-g expression in the immune
cells of mice immunized
subcutaneously with increasing doses of
human recombinant vaults containing
HIV Gag-1 spanning peptides in Figure
14 of R01 AI126914–01 and Figure 13 of
R44 AI128983–01
Dr. Jiang entered into a Voluntary
Settlement Agreement (Agreement) and
voluntarily agreed to the following:
(1) Respondent will have her research
supervised for a period of three (3) years
beginning on July 22, 2022 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of two senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of three (3) years
from the effective date of this
Agreement. The committee will review
Respondent’s primary data on a
quarterly basis and submit a report to
ORI at six (6) month intervals setting
forth the committee meeting dates and
Respondent’s compliance with
appropriate research standards and
E:\FR\FM\05AUN1.SGM
05AUN1
48036
Federal Register / Vol. 87, No. 150 / Friday, August 5, 2022 / Notices
confirming the integrity of Respondent’s
research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving Respondent’s
research. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the
Respondent’s data presented in the
proposed application, report,
manuscript, or abstract are supported by
the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing her submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that her
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that she has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude herself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
Dated: August 2, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–16867 Filed 8–4–22; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
lotter on DSK11XQN23PROD with NOTICES1
[Docket No. USCG–2022–0258]
National Maritime Security Advisory
Committee; Vacancies
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Request for applications.
AGENCY:
VerDate Sep<11>2014
17:20 Aug 04, 2022
Jkt 256001
The U.S. Coast Guard seeks
applications to fill two member
vacancies on the National Maritime
Security Advisory Committee
(Committee). This Committee provides
advice and makes recommendations to
the Secretary of Homeland Security, via
the Commandant of the U.S. Coast
Guard, on matters relating to national
maritime security, including on
enhancing the sharing of information
related to cybersecurity risks that may
cause a transportation security incident,
between relevant Federal agencies and
State, local, and tribal governments;
relevant public safety and emergency
response agencies; relevant law
enforcement and security organizations;
maritime industry; port owners and
operators; and terminal owners and
operators.
SUMMARY:
Your completed application
should reach the U.S. Coast Guard on or
before September 6, 2022.
ADDRESSES: Applications should
include a cover letter expressing interest
in an appointment to the National
Maritime Security Advisory Committee
and a resume detailing the applicant’s
relevant experience for the position
applied for, with a brief biography.
Incomplete applications will not be
considered. Applications should be
submitted via email with the subject
line ‘‘Application for NMSAC’’ to
ryan.f.owens@uscg.mil.
FOR FURTHER INFORMATION CONTACT: Mr.
Ryan Owens, Alternate Designated
Federal Officer of the National Maritime
Security Advisory Committee;
telephone: 202–372–1108 or email at
ryan.f.owens@uscg.mil
SUPPLEMENTARY INFORMATION: The
National Maritime Security Advisory
Committee is a Federal advisory
committee. The Committee was
established on December 4, 2018, by
§ 602 of the Frank LoBiondo Coast
Guard Authorization Act of 2018, Public
Law 115–282, 132 Stat. 4192, and is
codified in 46 U.S.C. 70112. The
Committee operates under the
provisions of the Federal Advisory
Committee Act, (5 U.S.C. Appendix),
and 46 U.S.C. 15109. The National
Maritime Security Advisory Committee
provides advice, consults with, and
makes recommendations to the
Secretary of Homeland Security, via the
Commandant of the Coast Guard, on
matters relating to national maritime
security, including on enhancing the
sharing of information related to
cybersecurity risks that may cause a
transportation security incident,
between relevant Federal agencies
and—
DATES:
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
A. State, local, and tribal
governments;
B. relevant public safety and
emergency response agencies;
C. relevant law enforcement and
security organizations;
D. maritime industry;
E. port owners and operators; and
F. terminal owners and operators.
The Committee is required to meet at
least once a year in accordance with 46
U.S.C. 15109(a). We expect the
Committee will hold meetings at least
twice a year, but it may meet more
frequently.
All members serve at their own
expense and receive no salary or other
compensation from the Federal
Government. Members may be
reimbursed for travel and per diem in
accordance with Federal Travel
regulations.
Under the provisions in 46 U.S.C.
15109(f)(6), if you are appointed as a
member of the Committee, your
membership term will expire on
December 31 of the third full year after
the effective date of your appointment.
In this solicitation for Committee
members, we will consider applications
for two (2) positions:
• Facilities owners and operators.
• State and local governments.
Each member of the Committee must
have particular expertise, knowledge,
and experience in matters relating to the
function of the Committee, which is to
advise the Secretary of Homeland
Security on the matters described above.
Consistent with 46 U.S.C. 15109(f)(4),
Committee members are required to
apply for, obtain, and maintain a
government national security clearance
at the Secret level. The U.S. Coast Guard
will sponsor and assist candidates with
this process.
In order for the Department, to fully
leverage broad-ranging experience and
education, the National Maritime
Security Advisory Committee must be
diverse with regard to professional and
technical expertise. The Department is
committed to pursuing opportunities,
consistent with applicable law, to
compose a committee that reflects the
diversity of the nation’s people.
If you are interested in applying to
become a member of the Committee,
email your cover letter and resume
along with the brief biography to
ryan.f.owens@uscg.mil via the
transmittal method in the ADDRESSES
section by the deadline in the DATES
section of this notice.
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 87, Number 150 (Friday, August 5, 2022)]
[Notices]
[Pages 48034-48036]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16867]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Janina
Jiang, M.D., Ph.D. (Respondent), former Assistant Researcher in the
Department of Pathology & Laboratory Medicine at the David Geffen
School of
[[Page 48035]]
Medicine, University of California, Los Angeles (UCLA). Respondent
engaged in research misconduct in research included in grant
applications submitted for U.S. Public Health Service (PHS) funds,
specifically R43 CA228629-01 submitted to the National Cancer Institute
(NCI), National Institutes of Health (NIH), UL1 TR000124 submitted to
the National Center for Advancing Translational Sciences (NCATS), NIH,
and P01 AI131294-01, R01 AI126914-01, R21 AI131013-01, R21 AI131451-01,
R21 AI131451-01A1, R21 AI142068-01, R43 AI136224-01, R44 AI126960-01,
and R44 AI128983-01 submitted to the National Institute of Allergy and
Infectious Diseases (NIAID), NIH. The administrative actions, including
supervision for a period of three (3) years, were implemented beginning
on July 22, 2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Janina Jiang, M.D., Ph.D., University of California, Los Angeles:
Based on the report of an investigation conducted by UCLA and
additional analysis conducted by ORI in its oversight review, ORI found
that Dr. Janina Jiang, former Assistant Researcher in the Department of
Pathology & Laboratory Medicine at the David Geffen School of Medicine,
UCLA, engaged in research misconduct in research included in grant
applications submitted for PHS funds, specifically R43 CA228629-01
submitted to NCI, NIH, UL1 TR000124 submitted to NCATS, NIH, and P01
AI131294-01, R01 AI126914-01, R21 AI131013-01, R21 AI131451-01, R21
AI131451-01A1, R21 AI142068-01, R43 AI136224-01, R44 AI126960-01, and
R44 AI128983-01 submitted to NIAID, NIH.
ORI found that Respondent engaged in research misconduct by
knowingly and recklessly falsifying and/or fabricating flow cytometry
data that were included in the following eleven (11) grant applications
submitted for PHS funds:
R43 CA228629-01, ``CTL Based Therapeutic Vaccine to
Prevent or Interrupt HPV Mediated Oncogenesis,'' submitted to NCI, NIH,
Awarded Project Dates: September 18, 2018-February 29, 2020.
UL1 TR000124, ``UCLA Clinical and Translational Science
Institute,'' submitted to NCATS, NIH, Awarded Project Dates: June 1,
2011-August 31, 2016.
P01 AI131294-01, ``Defining Factors Controlling HIV
Rebound,'' submitted to NIAID, NIH, Awarded Project Dates: August 10,
2017-July 31, 2022.
R01 AI126914-01, ``A Recombinant Human Vault CTL-Based HIV
Vaccine Component,'' submitted to NIAID, NIH, on December 23, 2015.
R21 AI131013-01, ``A Novel Cellular Immune Zika Vaccine,''
submitted to NIAID, NIH, on June 14, 2016.
R21 AI131451-01, ``A Novel Therapeutic Vaccine for HPV
Oncogenesis,'' submitted to NIAID, NIH, on June 14, 2016.
R21 AI131451-01A1, ``A Novel Therapeutic Vaccine for HPV
Oncogenesis,'' submitted to NIAID, NIH, on June 13, 2017.
R21 AI142068-01, ``A Novel Therapeutic Vaccine for HPV
Oncogenesis,'' submitted to NIAID, NIH, on February 12, 2018.
R43 AI136224-01, ``Development of A Novel Pan-Serovar
Vaccine for Chlamydia,'' submitted to NIAID, NIH, on April 5, 2017.
R44 AI126960-01, ``Novel Pan-Serovar Vaccine for
Chlamydia,'' submitted to NIAID, NIH, on January 4, 2016.
R44 AI128983-01, ``Design of a Novel CTL Retargeting
Therapeutic HIV Vaccine,'' submitted to NIAID, NIH, on April 2, 2016.
ORI found that Respondent knowingly and recklessly falsified and/or
fabricated flow cytometry data to represent interferon-[gamma] (IFN-
[gamma]) expression in immune cells of mice administered with human
recombinant vaults such that the represented data were incompatible
with the raw experimental data. Specifically, Respondent falsified and/
or fabricated flow cytometry data to represent:
IFN-[gamma] expression in the immune cells of mice
injected subcutaneously or intranasally with human recombinant vaults
containing HIV Gag peptides such that the vaccinated arm of the
experiment showed antigen-specific T-cell responses in:
--Figure 6 of UL1 TR000124
--Figure 2 of R43 CA228629-01
--Figure 8 of R21 AI131451-01
--Figure 9 of R21 AI131451-01A1
--Figure 9 of R44 AI126960-01
--Figure 3 of R43 AI136224-01
--Figure 9 of R21 AI131013-01
--Figure 7 of R01 AI126914-01
--Figure 7 of R44 AI128983-01
--Figures 8A and 8B of R21 AI142068-01
increased IFN-[gamma] expression in the immune cells of
mice injected with human recombinant vaults containing HPV peptides in
Figure 3 of R43 CA228629-01
dose-dependent increase in IFN-[gamma] expression in the
immune cells of mice injected with human recombinant vaults containing
HIV Gag peptides in Figure 8 of P01 AI131294-01 and Figure 8C of R21
AI142068-01
IFN-[gamma] expression in the immune cells of mice
administered intranasally with human recombinant vaults containing HPV
peptides in Figure 10 of R21 AI131451-01A1 and Figure 10 of R21
AI142068-01
IFN-[gamma] expression in the immune cells of mice
administered orally with human recombinant vaults containing HIV Gag
peptides in Figure 11 of R21 AI131451-01A1 and Figure 9 of R21
AI142068-01
IFN-[gamma] expression in the immune cells of mice
immunized subcutaneously with increasing doses of human recombinant
vaults containing HIV Gag-1 spanning peptides in Figure 14 of R01
AI126914-01 and Figure 13 of R44 AI128983-01
Dr. Jiang entered into a Voluntary Settlement Agreement (Agreement)
and voluntarily agreed to the following:
(1) Respondent will have her research supervised for a period of
three (3) years beginning on July 22, 2022 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of two senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for a period of three (3) years from the effective date of
this Agreement. The committee will review Respondent's primary data on
a quarterly basis and submit a report to ORI at six (6) month intervals
setting forth the committee meeting dates and Respondent's compliance
with appropriate research standards and
[[Page 48036]]
confirming the integrity of Respondent's research.
ii. The committee will conduct an advance review of each
application for PHS funds, or report, manuscript, or abstract involving
Respondent's research. The review will include a discussion with
Respondent of the primary data represented in those documents and will
include a certification to ORI that the Respondent's data presented in
the proposed application, report, manuscript, or abstract are supported
by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing her submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that her participation was not proposed on a research project
for which an application for PHS support was submitted and that she has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude herself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
Dated: August 2, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-16867 Filed 8-4-22; 8:45 am]
BILLING CODE 4150-31-P
